Thallium/technetium subtraction scanning for primary hyperparathyroidism: scan sensitivity and effect on operative...

Area of Science:

• Endocrinology
• Nuclear Medicine
• Surgical Oncology

Background:

• Hypercalcemia, often asymptomatic, requires thorough parathyroid evaluation.
• Routine biochemical tests (SMA-12) can initially detect elevated calcium levels.
• Parathyroid disorders are a common cause of hypercalcemia.

Purpose of the Study:

• To evaluate the diagnostic utility of imaging studies for parathyroid adenomas in asymptomatic hypercalcemic patients.
• To assess the clinical outcomes of surgical and medical management for hypercalcemia.
• To determine the effectiveness of thallium/technetium subtraction and sestamibi scanning in localizing parathyroid pathology.

Main Methods:

• Retrospective analysis of 26 patients over ten years with elevated serum calcium and parathormone.
• Utilized thallium/technetium subtraction scintigraphy and technetium sestamibi scans for parathyroid localization.
• Correlated imaging findings with surgical outcomes and clinical follow-up.

Main Results:

• Twenty-four of 26 patients showed positive results on thallium/technetium subtraction studies.
• Two patients with negative imaging studies were managed medically with successful outcomes.
• All surgically treated patients achieved normocalcemia within a six-month follow-up, with operative times under one hour.

Conclusions:

• Thallium/technetium subtraction scintigraphy is a valuable tool for diagnosing hyperparathyroidism in asymptomatic patients.
• Surgical intervention for confirmed parathyroid adenomas leads to successful normalization of calcium levels.
• Non-operative management can be considered for select cases with negative imaging findings.